Value of MIBG in the Differential Diagnosis of Neurodegenerative Disorders

2020 ◽  
pp. 577-590
Author(s):  
Mitsuhiro Yoshita
Keyword(s):  
Differential Diagnosis ◽  
Neurodegenerative Disorders

Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders

2015 ◽  
Vol 27 (9) ◽  
pp. 1429-1438 ◽  
Author(s):  
Zheng-Yu Wang ◽  
Zhen-Min Han ◽  
Qi-Fei Liu ◽  
Wei Tang ◽  
Kui Ye ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Differential Diagnosis ◽  
Neurodegenerative Disorders ◽  
Meta Analysis ◽  
Lewy Bodies ◽  
Cochrane Library ◽  
Random Effects Models ◽  
Significant Difference ◽  
Meta Analyses

ABSTRACTBackground:The etiology and pathogenesis of neurodegenerative disorders has yet to be elucidated, so their differential diagnosis is a challenge. This is especially true in differentiating Alzheimer's disease (AD), dementia with Lewy bodies (DLB), Parkinson disease (PD), and multiple system atrophy (MSA).Methods:A total of 11 eligible articles were identified by search of electronic databases including PubMed, Springer Link, Elsevier, and the Cochrane Library, up to June 2014. In meta-analyses, standardized mean differences (SMD), with 95% confidence intervals (CI), comparing cerebrospinal fluid (CSF) measures of α-synuclein between the above conditions were calculated using random-effects models.Results:CSF α-synuclein concentrations were significantly higher in AD compared to DLB [SMD: 0.32, 95% CI: (0.02, 0.62), z = 2.07, P = 0.038]; PD [SMD: 0.87, 95% CI: (0.15, 1.58), z = 2.38, P = 0.017]; or MSA [SMD: 1.14, 95% CI: (0.15, 2.14), z = 2.25, P = 0.025]. However, no significant difference was found between patients with AD and neurological cognitively normal controls [SMD: 0.02, 95% CI: (−0.21, 0.24), z = 0.13, P = 0.894].Conclusions:Results of these meta-analysis suggest that quantification of CSF α-synuclein could help distinguish AD from other neurodegenerative disorders such as DLB, PD, or MSA.

scholarly journals Role of neuro-sonography of peripheral nerves as a diagnostic and a differentiation tool of amyotrophic lateral sclerosis

2021 ◽  
Vol 57 (1) ◽  
Author(s):  
Rana Zakaria Ahmed Mohamed ◽  
Haitham Hamdy Salem ◽  
Hossam Moussa El-Sayed Sakr ◽  
Hossam-Eldin Mahmoud Afifi ◽  
Ahmed Mohammed Elsadek ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Differential Diagnosis ◽  
Early Diagnosis ◽  
Motor Neuron ◽  
Motor Neuron Disease ◽  
Neurodegenerative Disorders ◽  
Peripheral Nerves ◽  
Radiological Criteria ◽  
Lateral Sclerosis

Abstract Background Motor neuron disease is a heterogeneous group of progressive neurodegenerative disorders, most common of which is amyotrophic lateral sclerosis (ALS). There are many clinical and radiological criteria to diagnose amyotrophic lateral sclerosis and to differentiate it from other motor neuron disease and neurodegenerative disorders. Neuro-sonography is one of the easily applied tools to diagnose and differentiate ALS. ALS diagnosis is delayed up to 3 years according to some authors due to the wide differential diagnosis, with cervical degeneration being a common misdiagnosis. The objective of this study was to evaluate the role of neuro-sonography in diagnosis and differentiation of amyotrophic lateral sclerosis from other causes of progressive mixed upper and lower motor neuron lesion. Results A total neuro-sonography score at a cut-off point (≤ 127) predicted patients with ALS, with good (85%) accuracy, sensitivity = 73% and specificity = 83% (p < 0.01) and Lt median arm score at a cut-off point (≤ 6) predicted patients with ALS, with good (88%) accuracy, sensitivity = 86% and specificity = 86% (p < 0.01) and the median nerve at the arm level was the most sensitive and specific nerve to predict patients with ALS. Conclusion Neuro-sonography of peripheral nerves is a recent, noninvasive, accessible technique that can be used in early diagnosis of ALS.

scholarly journals Late Onset Neurodegeneration with Brain-Iron Accumulation Presenting as Parkinsonism

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Robert Fekete
Keyword(s):  
Differential Diagnosis ◽  
Neurodegenerative Disorders ◽  
Late Onset ◽  
Iron Accumulation ◽  
Atypical Parkinsonism ◽  
Brain Iron ◽  
Dopamine Transporter Imaging ◽  
Mri Brain ◽  
Abnormal Brain ◽  
Brain Iron Deposition

Neurodegeneration with brain-iron accumulation (NBIA) encompasses a family of neurodegenerative disorders connected by evidence of abnormal brain iron deposition. Advances in imaging and genetic testing expanded the clinical spectrum of these disorders. Here, a case of parkinsonism and dystonia with orofacial stereotypies is presented. While the patient was initially diagnosed with Parkinson’s disease and placed on levodopa therapy, dopamine transporter imaging via (123)I-FP-CIT SPECT (DaTSCAN) was normal. MRI brain showed “eye of the tiger” sign on T2 weighted imaging. NBIA should be considered in the differential diagnosis of atypical parkinsonism.

Alpha-synuclein Levels in the Differential Diagnosis of Lewy Bodies Dementia and Other Neurodegenerative Disorders

2020 ◽  
Vol 34 (3) ◽  
pp. 220-224 ◽  
Author(s):  
Ioannis Mavroudis ◽  
Foivos Petridis ◽  
Symela Chatzikonstantinou ◽  
Dimitrios Kazis
Keyword(s):  
Differential Diagnosis ◽  
Neurodegenerative Disorders ◽  
Lewy Bodies ◽  
Alpha Synuclein

Clusterin CSF levels in differential diagnosis of neurodegenerative disorders

2016 ◽  
Vol 361 ◽  
pp. 117-121 ◽  
Author(s):  
Hana Přikrylová Vranová ◽  
Eva Hényková ◽  
Jan Mareš ◽  
Michaela Kaiserová ◽  
Kateřina Menšíková ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Neurodegenerative Disorders ◽  
Csf Levels

scholarly journals Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders

2018 ◽  
Vol 45 (9) ◽  
pp. 1557-1566 ◽  
Author(s):  
Flavio Nobili ◽  
◽  
Cristina Festari ◽  
Daniele Altomare ◽  
Federica Agosta ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Neurodegenerative Disorders ◽  
Fdg Pet ◽  
Automated Assessment

Tumor Diagnosis

1982 ◽  
Vol 40 ◽  
pp. 262-265
Author(s):  
Bruce Mackay
Keyword(s):  
Electron Microscopy ◽  
Transmission Electron Microscopy ◽  
Differential Diagnosis ◽  
Light Microscopy ◽  
Clinical Examination ◽  
Ultrastructural Study ◽  
Diagnostic Procedures ◽  
Specific Diagnosis ◽  
Transmission Electron ◽  
Microscopic Diagnosis

The broadest application of transmission electron microscopy (EM) in diagnostic medicine is the identification of tumors that cannot be classified by routine light microscopy. EM is useful in the evaluation of approximately 10% of human neoplasms, but the extent of its contribution varies considerably. It may provide a specific diagnosis that can not be reached by other means, but in contrast, the information obtained from ultrastructural study of some 10% of tumors does not significantly add to that available from light microscopy. Most cases fall somewhere between these two extremes: EM may correct a light microscopic diagnosis, or serve to narrow a differential diagnosis by excluding some of the possibilities considered by light microscopy. It is particularly important to correlate the EM findings with data from light microscopy, clinical examination, and other diagnostic procedures.

Insights into amyloid disease from fly models

2014 ◽  
Vol 56 ◽  
pp. 69-83 ◽  
Author(s):  
Ko-Fan Chen ◽  
Damian C. Crowther
Keyword(s):  
Drosophila Melanogaster ◽  
Neurodegenerative Disorders ◽  
Amyloid Β ◽  
Amyloid Β Peptide ◽  
Disease Pathogenesis ◽  
Amyloid Aggregates ◽  
Aβ Amyloid ◽  
Polypeptide Chains ◽  
Amyloid Diseases

The formation of amyloid aggregates is a feature of most, if not all, polypeptide chains. In vivo modelling of this process has been undertaken in the fruitfly Drosophila melanogaster with remarkable success. Models of both neurological and systemic amyloid diseases have been generated and have informed our understanding of disease pathogenesis in two main ways. First, the toxic amyloid species have been at least partially characterized, for example in the case of the Aβ (amyloid β-peptide) associated with Alzheimer's disease. Secondly, the genetic underpinning of model disease-linked phenotypes has been characterized for a number of neurodegenerative disorders. The current challenge is to integrate our understanding of disease-linked processes in the fly with our growing knowledge of human disease, for the benefit of patients.

Sign in / Sign up

Export Citation Format

Share Document